afuresertib + carfilzomib

**afuresertib + carfilzomib** is an experimental combination therapy used primarily in research for the treatment of relapsed/refractory multiple myeloma. - **Afuresertib** is an oral, small molecule inhibitor of AKT, a key kinase in the PI3K/AKT pathway that is constitutively active in many hematologic malignancies, promoting cell survival and drug resistance. By inhibiting AKT, afuresertib induces apoptosis and suppresses proliferation in tumor cells[2]. - **Carfilzomib** is a selective, irreversible inhibitor of the 20S proteasome, the proteolytic core particle of the 26S proteasome. This leads to accumulation of polyubiquitinated proteins, resulting in cell cycle arrest and apoptosis, particularly in multiple myeloma cells[1][3]. The combination is being investigated for possible synergistic antimyeloma effects, given the distinct but complementary mechanisms of action of each agent. Early clinical investigations suggest the combination is under study in relapsed/refractory multiple myeloma[2].